Open Access

CPSF3 is a promising prognostic biomarker and predicts recurrence of non‑small cell lung cancer

  • Authors:
    • Yue Ning
    • Wanxia Liu
    • Xiaoying Guan
    • Xiaobin Xie
    • Yajie Zhang
  • View Affiliations

  • Published online on: July 24, 2019     https://doi.org/10.3892/ol.2019.10659
  • Pages: 2835-2844
  • Copyright: © Ning et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cleavage polyadenylation specificity factor (CPSF) is the core component of the 3'‑end processing complex, which determines the site of 3'‑end cleavage interactions of specific sequence elements within pre‑mRNAs. The present study revealed that all members of the CPSF complex were overexpressed in lung cancer tissue from The Cancer Genome Atlas (TCGA) Lung Cancer Cohort compared with normal lung tissue. Analysis of overall survival and recurrence‑free survival verified that only CPSF3 was associated with prognosis and recurrence of lung adenocarcinoma (LUAD), and thus could be a promising biomarker. Additionally, receiver operating characteristic curve analysis revealed that CPSF3 may function as a diagnostic biomarker to distinguish between two histological subtypes of non‑small cell lung cancer. Furthermore, analysis of the association of CPSF3 expression with clinicopathological parameters indicated that CPSF3 was associated with smoking history, tumor diameter, lymph node metastasis, clinical stage and radiation therapy in LUAD. Additionally, analysis of the DNA methylation data of the TCGA‑LUAD Cohort revealed that CPSF3 DNA CpG sites (cg12057242 and cg25739938) were generally hypomethylated in LUAD compared with normal lung tissue. Correlation analysis identified the CPSF3 DNA CpG site cg25739938 to be negatively correlated with CPSF3 expression, while no correlation was identified with cg12057242. In addition, correlation analysis demonstrated that the overexpression of CPSF3 was correlated with CPSF3 DNA copy number variants (CNAs). The findings indicate that abnormal expression of CPSF3 may be caused by DNA CNAs; and DNA hypermethylation and function may be a promising diagnostic and prognostic indicator for LUAD.

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ning, Y., Liu, W., Guan, X., Xie, X., & Zhang, Y. (2019). CPSF3 is a promising prognostic biomarker and predicts recurrence of non‑small cell lung cancer. Oncology Letters, 18, 2835-2844. https://doi.org/10.3892/ol.2019.10659
MLA
Ning, Y., Liu, W., Guan, X., Xie, X., Zhang, Y."CPSF3 is a promising prognostic biomarker and predicts recurrence of non‑small cell lung cancer". Oncology Letters 18.3 (2019): 2835-2844.
Chicago
Ning, Y., Liu, W., Guan, X., Xie, X., Zhang, Y."CPSF3 is a promising prognostic biomarker and predicts recurrence of non‑small cell lung cancer". Oncology Letters 18, no. 3 (2019): 2835-2844. https://doi.org/10.3892/ol.2019.10659